US/UK/Canada

Share

Contacts

  • Orexo
    Box 303 751 05 Uppsala
    +46 (0)18 780 88 00
    +46 (0)18 780 88 88
    http://www.orexo.com

    • Quotes

    With the acquisition of the rights to two digital health products from GAIA and the appointment of Dennis, a thought leader in the digital health industry in the US, we are well positioned to lead this development within the complementary disease areas of our pharmaceutical business.
    Nikolaj Sørensen, President and CEO
    Our strategy is to focus on solutions with scientifically proven therapeutic effect which will benefit the healthcare system as a whole and more importantly patients.
    Nikolaj Sørensen, CEO, about Digital Therapies
    I am convinced that DTx will become an integral and natural part of addiction treatment in the future. This digital therapy for OUD patients is perfectly positioned with Orexo’s competences and commercial organization in the US.
    Nikolaj Sørensen, President and CEO
    Mundipharma Australia has been a good partner in the approval process and we are confident that their experience and infrastructure will create a strong foundation for a successful launch of Zubsolv®
    Nikolaj Sørensen, President and CEO
    Pick a time period -
    Tags ( Active)

    Interim Report Q1 2017

    Financial overview Q1 2017 · Total net revenues SEK 127.4 million (151.0) · Zubsolv® net revenue SEK 114.1 million (98.4) · EBIT SEK -23.2 million (-26.2) · EBITDA SEK -18.1 million (-19.4) · Earnings per share, before and after dilution, SEK -1.00/-1.00 (-1.00/-1.00) · Cash flow from operating activities SEK 28.2 million (33.5) · Cash and cash equivalents SEK 250.6 million (233.0) · Guidance issued in connection with Full Year Report 2016 confirmed Other highlights Q1 2017 · Completion of another bond buyback program amounting to a nominal value of SEK 59

    Interim Report January-September 2016

    Strong Zubsolv® and Abstral® revenue growth. Third quarter 2016  · Total net revenues MSEK 181.9 (139.5).   · Zubsolv net revenue MSEK 142.8 (110.8). · Net earnings MSEK 36.0 (-46.1).  · Earnings per share, before and after dilution, SEK 1.04 (-1.33). · Cash flow from operating activities MSEK 31.2 (-79.5). · Cash and cash equivalents MSEK 276.9 (201.2).  · The US Department of Health and Human Services (HHS) announced an increase in buprenorphine patient cap from 100 to 275.  · The Congress signed CARA1into law which among others will expand the

    Interim Report January-June 2016

    Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2015. Positive cash flow and EBIT. Expansion of Zubsolv® to new markets and improved market access position in the US. Second quarter 2016  · Total net revenues MSEK 188.2 (126.5).   · Zubsolv net revenue MSEK 178.2 (91.1). · Earnings after tax MSEK 5.0 (-84.6).  · Earnings per share SEK 0.14 (-2.46). · Cash flow from operating activities MSEK 20.0 (-35.6). · Cash and cash equivalents MSEK 252.9 (282.1).  · Zubsolv was selected by

    Interim Report January-March 2016

    Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2015. Orexo reports positive cash flow for the quarter First quarter 2016 · Total net revenues MSEK 151.0 (149.0). · Zubsolv® net revenue MSEK 98.4 (94.5). · Earnings after tax MSEK -34.5 (-15.5). · Earnings per share SEK -1.0 (-0.45). · Cash flow from operating activities MSEK 22.5 (6.5). · Cash and cash equivalents MSEK 233.0 (289.3). · AstraZeneca acquired all rights to Orexo´s OX-CLI project for MUSD 5. The agreement also

    Full year report January-December 2015

    Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2014. 2015 – a year of investments and growth. Zubsolv® revenue growth of83 percent. Fourth quarter 2015 ▪      Total net revenues amounted to MSEK 228.3 (220.5). ▪      Zubsolv net revenue amounted to MSEK 120.3 (79.5). ▪      Earnings after tax were MSEK -51.8 (51.6). ▪      Earnings per share were SEK -1.50 (1.50). ▪      Cash flow from operating activities amounted to MSEK 6.3 (-7.3). ▪      Orexo received MGBP 5 milestone payment

    Orexo AB focuses its business and reduces costs

    Uppsala, Sweden - March 6, 2012 - Orexo AB is focusing its development activities to the three proprietary programs OX219, OX51 and OX27. The total requirement for resources will thereby be reduced with up to 35 full time employees.The personnel reduction, which will have full effect in 2013, is expected to lower the costs by a total of SEK 30 million annually. Negotiations with trade union representatives will commence immediately. The reduction in personnel is expected to be completed during the second quarter of 2012."The focus of our business activities will now be fully in line

    Sublinox (Edluar) approved in Canada

    Uppsala, Sweden, July 25 2011 – The insomnia drug Sublinox (Edluar) has been approved in Canada. Meda and its partner Valeant expect to begin the launch in the fourth quarter 2011. Sublinox will be marketed by the joint venture between Meda and Valeant, Meda Valeant Pharma Canada Inc. Meda has global rights to the drug and markets it in the USA since 2009 under the name Edluar. Orexo, who has developed the drug, is entitled to royalties on sales.The approval is for short-term treatment of insomnia. Sublinox is based on Orexo's sublingual tablet technology. The drug is placed under the

    Orexo AB (publ.) – Year-end Report January-December 2009

    Uppsala, February 17, 2010 Orexo AB (publ) – Year-end Report January–December 2009 Key events during the year • Net revenues totaled MSEK 236.1 (233.3). • The loss after tax was MSEK 98.1 (loss: 103.1). • The loss per share amounted to a loss of SEK 4.32 (loss: 4.77). • Cash and cash equivalents at year-end totaled MSEK 87.4 (188.2). • Abstral was launched in UK, Germany, France, Spain and Greece. • In March, the FDA approved Orexo’s product Edluar for the short-term treatment of insomnia. The approval resulted in Orexo receiving a milestone payment of MUSD 5 from Meda. • In August, Orexo

    Orexo AB (publ) – Interim report January-September 2009

    Uppsala, November 10, 2009 Orexo AB (publ) – Interim report January-September 2009 Key events during the period • Net revenues amounted to MSEK 208.2 (141.2). • The loss after tax was MSEK 40.1 (loss: 88,6). • The loss per share was SEK 1.78 (loss: 4.10). • Cash and cash equivalents at the end of the quarter totaled MSEK 107.1 (195.7). • In March, the US Food and Drug Administration (FDA) approved Orexo’s Edluar product for the treatment of short-term insomnia. The approval meant that Orexo received a milestone payment of MUSD 5 from Meda. • In February, Orexo signed an exclusive

    Orexo AB (publ) – Interim report, January - June 2009

    Key events during the period • Net revenues amounted to MSEK 144.6 (80.2). • The loss after tax was MSEK 30.5 (loss: 90.5). • The loss per share was SEK 1.38 (loss: 4.19). • Cash and cash equivalents at the end of the quarter amounted to MSEK 137.2 (247.1). • The US Food and Drug Administration (FDA) approved Orexo’s EdluarTM product for the short-term treatment of insomnia. The approval meant that Orexo received a milestone payment from Meda of MUSD 5. • Orexo signed an exclusive development agreement with a large healthcare company. The agreement covers the development of Orexo’s OX17

    Orexo announces that its partner Meda has initiated the launch of EdluarTM in the USA

    Uppsala, Sweden, 18 August 2009 - Orexo (STO: ORX) confirms that Meda (STO: MEDA A) has initiated the launch the drug EdluarTM in the United States of America. The launch follows the US Food and Drug Administration’s (FDA) approval in March this year of EdluarTM 5 mg and 10 mg sublingual tablets for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Meda acquired exclusive worldwide commercialization rights for EdluarTM from Orexo in 2008. Orexo will receive royalty payments on Meda’s sales of EdluarTM in the USA. Commenting on the news, Torbjörn

    Orexo’s Edluar (Sublinox) receives FDA approval for the treatment of insomnia

    • Meda expects to launch Edluar in the USA during 2nd half of 2009• Orexo receives a milestone payment of USD 5 million from Meda• Orexo’s second major product approval in 12 monthsOrexo (NASDAQ-OMX:ORX) today announces that the US Food and Drug Administration (FDA) has approved Edluar (formerly Sublinox) 5 mg and 10 mg sublingual tablets for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Orexo’s partner Meda (NASDAQ-OMX: MEDA A) acquired the exclusive worldwide commercialization license for Edluar last year and they expect to launch the

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media